Market News AIOpen the app

Stifel says to buy Tandem Diabetes Care, setting a price target of $26.

OpinionRead the original at marketscreener.com
Good for TNDM

Stifel raised Tandem to Buy and set a $26 target. This is a favorable outside view, but the report gives no new sales or profit results; the upgrade still makes the story positive for Tandem.

TNDM · Tandem Diabetes Care

AI read · Good for TNDM

The AI's read

An outside firm's favorable view can draw attention to Tandem, but it does not change the company's products, sales, or profits by itself. The report offers no new business results, so the upgrade is a positive signal, not proof of stronger performance.

Get alerts for TNDM

Follow Tandem Diabetes Care (TNDM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TNDM
Free on the App Store and Google Play, or on the web.